Bremelanotide

Bremelanotide
Clinical data
Pronunciation	/ˌbrɛmɪˈlænətaɪd/ ⓘ
Trade names	Vyleesi
Other names	PT-141; Rekynda, bremelanotide acetate (USAN US)
AHFS/Drugs.com	Monograph
MedlinePlus	a619054
License data	US DailyMed: Bremelanotide;
Routes of; administration	Subcutaneous
Drug class	Central nervous system agent
ATC code	G02CX05 (WHO) ;
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Bioavailability	SCTooltip Subcutaneous injection: ~100%
Protein binding	21%
Metabolism	Hydrolysis of peptide bonds
Elimination half-life	2.7 hours
Excretion	Urine: 64.8%; Feces: 22.8%
Identifiers
	IUPAC name (3S,6S,9R,12S,15S,23S)-15-[(N-Acetyl-L-norleucyl)amino]-9-benzyl-6-{3-[(diaminomethylidene)amino]propyl}-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexaazacyclotricosane-23-carboxylic acid;
CAS Number	189691-06-3 ;
PubChem CID	9941379;
DrugBank	DB11653 ;
ChemSpider	8116997 ;
UNII	6Y24O4F92S;
KEGG	D06569 ;
ChEMBL	ChEMBL2070241 ;
CompTox Dashboard (EPA)	DTXSID40893711 ;
Chemical and physical data
Formula	C50H68N14O10
Molar mass	1025.182 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(C)N[C@@H](CCCC)C(N[C@@H]1C(N[C@@H](CC2=CNC=N2)C(N[C@H](CC3=CC=CC=C3)C(N[C@@H](CCC/N=C(N)\N)C(N[C@@H](CC4=CNC5C=CC=CC45)C(N[C@@H](CCCCNC(C1)=O)C(O)=O)=O)=O)=O)=O)=O)=O;
	InChI InChI=1S/C50H68N14O10/c1-3-4-16-35(58-29(2)65)43(67)64-41-25-42(66)54-20-11-10-18-37(49(73)74)60-46(70)39(23-31-26-56-34-17-9-8-15-33(31)34)62-44(68)36(19-12-21-55-50(51)52)59-45(69)38(22-30-13-6-5-7-14-30)61-47(71)40(63-48(41)72)24-32-27-53-28-57-32/h5-9,13-15,17,26-28,35-41,56H,3-4,10-12,16,18-25H2,1-2H3,(H,53,57)(H,54,66)(H,58,65)(H,59,69)(H,60,70)(H,61,71)(H,62,68)(H,63,72)(H,64,67)(H,73,74)(H4,51,52,55)/t35-,36-,37-,38+,39-,40-,41-/m0/s1 ; Key:FFHBJDQSGDNCIV-MFVUMRCOSA-N ;
	(verify)

Bremelanotide, sold under the brand name Vyleesi, is a medication used to treat low sexual desire in women. Specifically it is used for low sexual desire which occurs before menopause and is not due to medical problems, psychiatric problems, or problems within the relationship. It is given by an injection just under the skin of the thigh or abdomen.

Common side effects include nausea, pain at the site of injection, and headache. It may also cause a temporary increase in blood pressure and decrease in heart rate after each dose, and darkening of the gums, face, and breasts. The medication is a peptide and acts by activating the melanocortin receptors.

Bremelanotide was approved for medical use in the United States in 2019. It was developed by Palatin Technologies. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.